Evidence map›Paper›PMID 40734632›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Dual-Ligand Strategy in Rh-Catalyzed Sequential Hydrofunctionalization of Valylene.

Yong-Kang Mei, Su-Yang Xu, Zhi-Hui Wang, Ding-Wei Ji, Qing-An Chen

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Dual-Ligand Strategy in Rh-Catalyzed Sequential Hydrofunctionalization of Valylene.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yong-Kang MeiDalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China.
Su-Yang XuDalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China.
Zhi-Hui WangDalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China.
Ding-Wei JiDalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China.
Qing-An ChenDalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China.ORCID https://orcid.org/0000-0002-9129-2656

Funding

National Natural Science Foundation of China 22201281
6 · The paper itself

Abstract

Controlling regio- and chemo-selectivity in transition-metal-catalyzed reactions involving coupling reagents with multiple reactive sites remains a significant challenge. In this study, a dual-ligand strategy is introduced to orthogonally regulate both nucleophilic and electrophilic sites in the rhodium-catalyzed sequential hydrofunctionalization of valylene. Leveraging the synergistic effects of bidentate and monodentate phosphine ligands, cyclic prenylation of 4-hydroxycoumarins is achieved with outstanding regio- and chemo-selectivity under basic conditions. Conversely, structurally reversed prenylation is selectively obtained using a dppb (1,4-bis(diphenylphosphino)butane)/DME (1,2-dimethoxyethane) ligand combination under acidic conditions. This efficient and versatile protocol is also applicable to pyrazol-5-one substrates, yielding high-value dihydropyrano[2,3-c]pyrazole analogs. Mechanistic studies suggest that the cyclic prenylation proceeds via C3- or O-propargylation, followed by Rh- or acid-promoted intermolecular annulation. It is hoped that this strategy will provide valuable insights for addressing selectivity challenges in transition-metal catalysis and inspire further developments in this field.

Indexed as

1, 3‐enynecoumarindual‐ligandRh catalysisskeleton‐divergence

Identifiers

PMID40734632
PMCPMC12561339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.